Innocan Pharma (INNPF) Research & Development (2024 - 2025)
Innocan Pharma's Research & Development came in at $161,000 for the quarter ended Dec 31, 2025, down 50.2% from $323,000 a year earlier and down 61.2% from the prior quarter.
Powered by 
Analysis
Innocan Pharma (INNPF) Research & Development (2024 - 2025) Analysis & Trends
For the year ended Dec 31, 2025, Innocan Pharma's Research & Development was $932,000, down 39.8% from the prior year.
- Going back by year, Research & Development was $1.55 million in the year ended Dec 31, 2024 (-13.8%) and $1.8 million in the year ended Dec 31, 2023.
- The figure for the quarter ended Dec 31, 2025 represents the lowest quarterly Research & Development in data going back to the quarter ended Mar 31, 2024.
- Year-over-year, Research & Development increased in 1 of the last four quarters, with an average decline of 39.1%.
- Business Quant data shows INNPF's Research & Development at $415,000 (quarter ended Sep 30, 2025), $176,000 (quarter ended Jun 30, 2025) and $180,000 (quarter ended Mar 31, 2025) in the three quarters before the quarter ended Dec 31, 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,359.75 Bn | 1,333.37 Bn | 20.46 Bn | 4.25 Bn |
| 2 | Johnson & Johnson | 688.76 Bn | 608.62 Bn | 17.30 Bn | 4.65 Bn |
| 3 | AbbVie | 521.69 Bn | 489.75 Bn | 13.12 Bn | 2.57 Bn |
| 4 | Merck | 364.31 Bn | 327.31 Bn | 13.19 Bn | 4.54 Bn |
| 5 | Novartis Ag | 306.35 Bn | 279.93 Bn | - | - |
| 6 | Astrazeneca | 285.96 Bn | 259.56 Bn | 13.26 Bn | 3.89 Bn |
| 7 | Amgen | 251.88 Bn | 203.53 Bn | 7.58 Bn | 2.11 Bn |
| 8 | Gilead Sciences | 208.59 Bn | 183.61 Bn | 6.73 Bn | 1.61 Bn |
| 9 | Pfizer | 164.73 Bn | 112.38 Bn | 12.56 Bn | 3.02 Bn |
| 10 | Innocan Pharma | 5.78 Mn | 1.73 Mn | 4.43 Mn | 161,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 161,000.00 |
| Sep 30, 2025 | 415,000.00 |
| Jun 30, 2025 | 176,000.00 |
| Mar 31, 2025 | 180,000.00 |
| Dec 31, 2024 | 323,000.00 |
| Sep 30, 2024 | 377,000.00 |
| Jun 30, 2024 | 425,000.00 |
| Mar 31, 2024 | 424,000.00 |
API Access
Innocan Pharma Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=INNPF&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "INNPF", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=INNPF&period=max&api_key=YOUR_API_KEY");
const data = await res.json();